A detailed history of Dimensional Fund Advisors LP transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 18,604 shares of IGMS stock, worth $165,389. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,604
Previous 37,034 49.77%
Holding current value
$165,389
Previous $254,000 20.87%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$6.28 - $17.68 $115,740 - $325,842
-18,430 Reduced 49.77%
18,604 $307,000
Q2 2024

Aug 09, 2024

SELL
$6.51 - $11.47 $15,747 - $27,745
-2,419 Reduced 6.13%
37,034 $254,000
Q4 2023

Feb 07, 2024

SELL
$3.94 - $8.79 $2,836 - $6,328
-720 Reduced 1.79%
39,453 $327,000
Q3 2023

Nov 09, 2023

SELL
$6.66 - $10.64 $80,452 - $128,531
-12,080 Reduced 23.12%
40,173 $335,000
Q2 2023

Aug 09, 2023

SELL
$8.86 - $14.0 $378,667 - $598,346
-42,739 Reduced 44.99%
52,253 $482,000
Q1 2023

May 12, 2023

BUY
$13.74 - $25.76 $677,588 - $1.27 Million
49,315 Added 107.96%
94,992 $1.31 Million
Q4 2022

Feb 09, 2023

BUY
$15.45 - $26.02 $123 - $208
8 Added 0.02%
45,677 $776,000
Q3 2022

Nov 10, 2022

SELL
$15.42 - $27.01 $408,337 - $715,251
-26,481 Reduced 36.7%
45,669 $1.04 Million
Q2 2022

Aug 12, 2022

BUY
$13.27 - $25.5 $211,669 - $406,750
15,951 Added 28.38%
72,150 $1.3 Million
Q1 2022

May 13, 2022

SELL
$13.42 - $29.73 $27,135 - $60,114
-2,022 Reduced 3.47%
56,199 $1.5 Million
Q4 2021

Feb 09, 2022

BUY
$27.59 - $66.39 $1.4 Million - $3.38 Million
50,848 Added 689.65%
58,221 $1.71 Million
Q3 2021

Nov 12, 2021

SELL
$65.76 - $90.65 $31,564 - $43,512
-480 Reduced 6.11%
7,373 $485,000
Q2 2021

Aug 12, 2021

BUY
$57.98 - $96.6 $455,316 - $758,599
7,853 New
7,853 $653,000

Others Institutions Holding IGMS

About IGM Biosciences, Inc.


  • Ticker IGMS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,969,000
  • Market Cap $258M
  • Description
  • IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...
More about IGMS
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.